secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRATED BIOPHARMA INC (INBP)
CIK:        0001016504
Form:       8-K
Filed at:   2025-09-23T23:59:59+00:00
Accession:  0001437749-25-029717
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integrated BioPharma Q4 rev $14.2M (+11.8%); net loss $0.2M on tax; FY net income $808k
--------------------------------------------------------------------------------

- Q4 revenue $14.2M vs $12.7M (+11.8%); operating income $589k vs $402k.
- Q4 net loss $178k ($0.01 loss per share) vs net income $268k ($0.01 EPS) prior year; tax expense $773k.
- FY2025 revenue $54.4M (+8.0%); net income $808k ($0.03 diluted EPS) vs $112k ($0.00 EPS) prior year.
- FY operating income $2.0M vs $251k; selling and administrative expenses flat.
- Weighted average diluted shares for FY 31.2M vs 30.9M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1016504/000143774925029717/0001437749-25-029717-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1016504/000143774925029717/inbp20250922_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-029717

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer